Aravive is currently conducting clinical trials of batiraxcept (formerly AVB-500), in combination with standard anticancer treatments in multiple indications.
Completed enrollment in the
AXLerate Phase 3 trial of batiraxcept
in platinum-resistant ovarian cancer. Click HERE for the AXLerate Phase 3 Trial
Completed enrollment in
Phase 1b/2 trials of batiraxcept
in clear cell renal cell carcinoma.
Now enrolling patients in a
Phase 1b/2 trial of batiraxcept
in pancreatic adenocarcinoma.
Now enrolling patients in the AXLerate Phase 3 trial of AVB-500 in platinum-resistant ovarian cancer.CLICK HERE FOR WWW.CLINICALTRIALS.GOVCLICK HERE FOR THE AXLerate PHASE 3 TRIAL
Now enrolling patients in a Phase 1b/2 trial of AVB-500 in clear cell renal cell carcinoma.CLICK HERE FOR WWW.CLINICALTRIALS.GOV
Now enrolling patients in a Phase 1b/2 trial of AVB-500 in pancreatic adenocarcinoma.CLICK HERE FOR WWW.CLINICALTRIALS.GOV
Batiraxcept targets GAS6/AXL signaling, an important driver of metastasis and resistance to anti-cancer drugs.
Our lead indication for batiraxcept is a registrational Phase 3 trial for the treatment of platinum resistant ovarian cancer. We are also evaluating batiraxcept in Phase 1b/2 trials for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma.
For the latest news, corporate presentation and investor information, visit the investor section of our site.